Takashi Ueki1, Tatsuya Manabe2, Shigetaka Inoue3, Jun Ienaga3, Naoki Yamanaka4, Takuya Egami5, Mikimasa Ishikawa6, Hiroyuki Konomi7, Akashi Ikubo8, Kinuko Nagayoshi2, Masafumi Nakamura2, Masao Tanaka9. 1. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Higashi-ku, Fukuoka, Japan tueki@surg1.med.kyushu-u.ac.jp. 2. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Higashi-ku, Fukuoka, Japan. 3. Japanese Red Cross Fukuoka Hospital, Minami-ku, Fukuoka, Japan. 4. Japanese Red Cross Yamaguchi Hospital, Yamaguchi-shi, Yamaguchi, Japan. 5. Japan Labor Health Welfare Organization, Kyushu Rosai Hospital, Kokuraminami-ku, Kitakyushu, Japan. 6. Japan Community Health Care Organization, Kyushu Hospital, Yahatanishi-ku, Kitakyushu, Japan. 7. Hamanomachi Hospital, Chuo-Ku, Fukuoka, Japan. 8. Japanese Red Cross Karatsu Hospital, Karatsu-shi, Saga, Japan. 9. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Higashi-ku, Fukuoka, Japan Shimonoseki City Hospital, Shimonoseki-shi, Yamaguchi, Japan.
Abstract
AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer. PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate. RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%). CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status. Copyright
AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer. PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate. RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%). CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status. Copyright
Authors: R Glynne-Jones; M R Hall; A Lopes; S Pearce; V Goh; S Bosompem; J Bridgewater; I Chau; H Wasan; B Moran; L Melcher; N P West; P Quirke; W-L Wong; S Beare; N Hava; M Duggan; M Harrison Journal: Heliyon Date: 2018-09-22